Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers
The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase I trial presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by researchers at The University of Texas MD Anderson Cancer Center.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.